A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

A Phase 1b/2 Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.

The study is divided into two parts: single agent FT-2102 followed by combination therapy.

Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dose confirmation followed by a Phase 2 investigation of clinical activity in up to 4 cohorts. During the dose confirmation, additional doses or altered dose schedules may be explored.

Part 2: An open-label study of FT-2102 in combination with other anti-cancer agents. Patients will be enrolled across 4 different disease cohorts, examining the effect of FT-2102 + azacitidine (glioma and chondrosarcoma), FT-2102 + nivolumab (hepatobiliary tumors), and FT-2102 + gemcitabine/cisplatin (intrahepatic cholangiocarcinoma). There will be a safety lead-in followed by a Phase 2 evaluation in up to four cohorts of patients.

Study Overview

• Status: Completed
• Conditions: Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme); Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas); Cohort 3a and 3b: Chondrosarcoma; Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma; Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
• Intervention / Treatment: Drug: FT-2102; Drug: Azacitidine; Biological: Nivolumab; Drug: Gemcitabine and Cisplatin

• Study Type: Interventional
• Enrollment (Actual): 93
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Australia
  • Melbourne, Australia, VIC 3000
    • Peter MacCallum Cancer Centre
  • Victoria
    • Heidelberg, Victoria, Australia, 3084
      • Austin Hospital
• France
  • Bordeaux, France, 33076
    • Centre de Lutte Contre Cancer (CLCC) - Institute Bergonie
  • Lyon, France
    • Centre de Lutte Cancre (CLCC) - Lyon
  • Marseille, France, 13385
    • Hospital De La Timone
  • Villejuif, France, 94800
    • Institut Gustave Roussy Cancer Campus
• Korea, Republic of
  • Seoul, Korea, Republic of, 03080
    • Seoul National University Hospital
  • Seoul, Korea, Republic of, 05505
    • Asan Medical Center
  • Seoul, Korea, Republic of, 06351
    • Samsung Medical Center
• Spain
  • Barcelona, Spain, 08035
    • Vall D'Hebron University Hospital
• United Kingdom
  • Glasgow, United Kingdom, G12 OYN
    • Cancer Research Beatson Institute
  • London, United Kingdom, SW3 6JJ
    • The Royal Marsden Hospital
• United States
  • Arizona
    • Gilbert, Arizona, United States, 85234
      • Banner MD Anderson
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado Anschutz Medical Campus
  • Florida
    • Miami, Florida, United States, 33136
      • University of Miami, Sylvester Comprehensive Cancer Center
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Northwestern University, Lurie Comprehensive Cancer Center
  • Iowa
    • Iowa City, Iowa, United States, 52242
      • University of Iowa, Holden Comprehensive Cancer Institute
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Massachusetts General Hospital
    • Boston, Massachusetts, United States, 02215
      • Dana Farber Cancer Institute
  • Michigan
    • Detroit, Michigan, United States, 48202
      • Henry Ford Hospital
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Washington University School of Medicine
  • New Jersey
    • New Brunswick, New Jersey, United States, 08901
      • Rutgers Cancer Institute of New Jersey
  • New York
    • New York, New York, United States, 10032
      • Columbia University Medical Center
  • Texas
    • Temple, Texas, United States, 76508
      • Baylor Scott and White Medical Center
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • University of Utah, Huntsman Cancer Hospital
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Medical College of Wisconsin, Froedtert Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria:

• Patients must have documented IDH1-R132 gene-mutated disease as evaluated by site
• Glioma: Advanced glioma that has recurred or progressed following standard therapy, or that has not responded to standard therapy.
• Hepatobiliary cancer that is relapsed/refractory or intolerant to approved standard-of-care therapy (including: hepatocellular carcinoma, bile duct carcinoma, intrahepatic cholangiocarcinoma or other hepatobiliary carcinomas)
• Chondrosarcoma that is relapsed or refractory and either locally advanced or metastatic and not amenable to complete surgical excision
• Intrahepatic cholangiocarcinoma that is advanced nonresectable or metastatic cholangiocarcinoma not eligible for curative resection or transplantation. Phase 1b/Safety Lead-in of Phase 2: relapsed or refractory disease. Combination Phase 2 (beyond Safety Lead-in): have received no more than 1 cycle of gemcitabine/cisplatin therapy
• Other solid tumors that have relapsed or refractory to standard-of-care therapy with no other available therapeutic options
• Good performance status
• Good kidney and liver function

Key Exclusion Criteria:

• Prior solid organ or hematopoietic cell transplant
• Prior treatment with IDH1 inhibitor (single agent cohorts only)
• Congestive heart failure (New York Heart Association Class III or IV) or unstable angina pectoris. Previous history of myocardial infarction within 1 year prior to study entry, uncontrolled hypertension or uncontrolled arrhythmias
• Unstable or severe, uncontrolled medical condition (e.g., unstable cardiac function, unstable pulmonary condition, including pneumonitis and/or interstitial lung disease, and uncontrolled diabetes)
• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
• PD-1 only: active autoimmune disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase 1b Dose Confirmation Single Agent (Cohorts 1a-5a)	Drug: FT-2102; FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
Experimental: Phase 2 Cohorts FT-2102 Single Agent (Cohorts 1a-5a)	Drug: FT-2102; FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
Experimental: Phase 1b and 2 Cohorts Combination (Cohorts 1b and 3b)	Drug: FT-2102; FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.; Drug: Azacitidine; Azacitidine will be administered per the site's standard of care.; Other Names: Vidaza
Experimental: Phase 1b and 2 Cohort Combination (Cohort 2b)	Drug: FT-2102; FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.; Biological: Nivolumab; Nivolumab will be administered per the site's standard of care.; Other Names: Opdivo
Experimental: Phase 1b and 2 Cohort Combination (Cohort 4b)	Drug: FT-2102; FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.; Drug: Gemcitabine and Cisplatin; Gemcitabine and cisplatin will be administered per the site's standard of care.; Other Names: Gemzar and Platinol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With a Dose Limiting Toxicity (DLT)	DLTs are AEs unrelated to the underlying disease and considered related to FT-2102. For non-hematologic AEs: Grade 3 or higher per CTCAE v 4.03 criteria except Grade 3 nausea, vomiting, diarrhea, or rash: lasting <72 hours (with optimal medical management) or clinically relevant Grade 3 or higher non-hematologic laboratory finding. For hematologic AEs: Grade 3 or higher thrombocytopenia or febrile neutropenia or Grade 4 or higher neutropenia lasting for >7 days.	Day 1-28
Overall Response Rate (ORR)	ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) as per RANO (2010) criteria for patients with high grade glioma (Cohorts 1a and 1b). For patients with low grade glioma, ORR is defined as CR+PR+minor response (MR) as per LGG RANO criteria (2011). For Cohorts 2-5, ORR is defined as CR+PR as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.	While on treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Plasma Concentration Versus Time Curve (AUC)	Area under the plasma concentration versus time curve (AUC) summarized for Cycle 1 and Cycle 2	Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Peak Plasma Concentration (Cmax)	Peak Plasma Concentration (Cmax) was summarized for Cycle 1 and Cycle 2.	Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Time of Peak Plasma Concentration (Tmax)	Time of peak plasma concentration (Tmax) was summarized for Cycle 1 and Cycle 2.	Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Time for Half of the Drug to be Absent in Blood Stream Following Dose (T 1/2)	Time for half of the drug to be absent in blood stream following dose (T 1/2)	Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Apparent Clearance (CL/F)	Rate at which drug is removed from the blood stream (CL/F).	Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Rate of Drug Distribution Within the Blood Stream (Vd/F)	Rate of drug distribution within the blood stream (Vd/F)	Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Olutasidenib Concentration Within Cerebro-spinal Fluid (CSF)	Olutasidenib concentration within CSF (Glioma Cohorts 1-A and 1-B only). Due to sparse data, analysis was not conducted by timepoint.	CSF sample for drug concentration was collected at Day 1 of Cycles 1 and 3 (each cycle is 28 days) and through study completion, up to 24 weeks, on average.
Progression-Free Survival (PFS)	Progression-Free Survival from time of entry on study. Progression-free survival (PFS) is defined as the time from the first dose to disease progression as determined by applicable disease criteria or death due to any cause, whichever was sooner. Disease progression as measured by the appropriate response criteria, unless deemed by the Investigator to be receiving clinical benefit	From time of entry on study through progression, up to 24 weeks, on average
Time to Progression (TTP)	Time to progression is defined as the time (in weeks) from start of treatment until disease specified progression.	From first dose of study drug through time of disease progression
Duration of Response (DOR)	Duration of response (DOR), defined as the time from the first response to documented disease progression as determined by applicable disease criteria. First response is defined as first observation of overall response of CR+PR+MR (glioma) or CR+PR (Cohort 2-5). Disease progression as measured by the appropriate response criteria, unless deemed by the Investigator to be receiving clinical benefit	From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 44 weeks
Overall Survival (OS)	Overall survival (OS), defined as the time in weeks from the first dose to death due to any cause or date last known alive at end of follow-up	From date of first dose until the date of death from any cause, assessed up to 101 weeks
Time to Response (TTR)	Time to response (TTR) in weeks. TTR is defined as the time from first dose to first response. First response is defined as first observation of overall response of CR+PR+MR (glioma) or CR+PR (Cohort 2-5).	Response may be observed from time of first dose through time of treatment discontinuation, up to 2 years.

Collaborators and Investigators

• Sponsor: Forma Therapeutics, Inc.
• Investigators: Study Director: Emma Barrett, Forma Therapeutics

Study record dates

Study Major Dates

• Study Start (Actual): November 1, 2018
• Primary Completion (Actual): May 24, 2021
• Study Completion (Actual): June 13, 2022

Study Registration Dates

• First Submitted: September 17, 2018
• First Submitted That Met QC Criteria: September 24, 2018
• First Posted (Actual): September 26, 2018

Study Record Updates

• Last Update Posted (Actual): November 18, 2023
• Last Update Submitted That Met QC Criteria: November 16, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: Olutasidenib
• Additional Relevant MeSH Terms: Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Astrocytoma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neoplasms, Connective Tissue; Sarcoma; Neoplasms; Glioblastoma; Glioma; Cholangiocarcinoma; Chondrosarcoma; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Antineoplastic Agents, Immunological; Immune Checkpoint Inhibitors; Nivolumab; Azacitidine; Gemcitabine
• Other Study ID Numbers: 2102-ONC-102

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No